研究発表

研究発表

Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection

Burdette, D. Hyrina, A. Song, Z. Beran, R. K. Cheung, T. Gilmore, S. Kobayashi, T. Li, L. Liu, Y. Niedziela-Majka, A. Medley, J. Mehra, U. Morganelli, P. Novikov, N. Niu, C. Tam, D. Tang, J. Wang, J. Yue, Q. Fletcher, S. P. Holdorf, M. M. Delaney, W. E. th Feierbach, B. Lazerwith, S.
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0134822. doi: 10.1128/aac.01348-22.

READ MORE(PUB MED)

Novel AAV-mediated genome editing therapy improves health and survival in a mouse model of methylmalonic acidemia

Zhang, S. Bastille, A. Gordo, S. Ramesh, N. Vora, J. McCarthy, E.Zhang, X. Frank, D. Ko, C. W. Wu, C. Walsh, N. Amarwani, S. Liao, J. Xiong, Q. Drouin, L. Hebben, M. Chiang, K. Chau, B. N.
PLoS One. 2022 Sep 20;17(9):e0274774. doi: 10.1371/journal.pone.0274774.

READ MORE(PUB MED)

Novel approach for verification of a human PBPK modeling strategy using chimeric mice in the health risk assessment of epyrifenacil

Hirasawa, K. Abe, J. Nagahori, H. Kitamoto, S
Toxicol Appl Pharmacol. 2023 Apr 15;465:116439. doi: 10.1016/j.taap.2023.116439. Epub 2023 Feb 27.

READ MORE(PUB MED)

A Novel Anti-HBV Agent, E-CFCP, restores Hepatitis B virus (HBV)-induced Senescence-associated Cellular Markers Perturbation in Human Hepatocytes

Takamatsu, Y. Hayashi, S. Kumamoto, H. Imoto, S. Tanaka, Y. Mitsuya, H. Higashi-Kuwata, N.
Virus Res. 2023 Mar 23;329:199094. doi: 10.1016/j.virusres.2023.199094.

READ MORE(PUB MED)

HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice

Uchida, T. Imamura, M. Hayes, C. N. Suehiro, Y. Teraoka, Y. Ohya, K. Aikata, H. Abe-Chayama, H. Ishida, Y. Tateno, C. Hara, Y. Hino, K. Okamoto, T. Matsuura, Y. Aizaki, H. Wake, K. Kohara, M. Liang, T. J. Oka, S. Chayama, K.
Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000335.

READ MORE(PUB MED)

Identification of SARS-CoV-2 M(pro) inhibitors containing P1′ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

Higashi-Kuwata, N. Tsuji, K. Hayashi, H. Bulut, H. Kiso, M. Imai, M. Ogata-Aoki, H. .Ishii, T. Kobayakawa, T. Nakano, K. Takamune, N. Kishimoto, N. Hattori, S. I. Das, D. Uemura, Y. Shimizu, Y. Aoki, M. Hasegawa, K. Suzuki, S. Nishiyama, A. Saruwatari, J. Shimizu, Y. Sukenaga, Y. Takamatsu, Y. Tsuchiya, K. Maeda, K. Yoshimura, K. Iida, S. Ozono, S. Suzuki, T. Okamura, T. Misumi, S. Kawaoka, Y. Tamamura, H. Mitsuya, H.
Nat Commun. 2023 Feb 25;14(1):1076. doi: 10.1038/s41467-023-36729-0.

READ MORE(PUB MED)

Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants

Yokokawa, H. Shinohara, M. Teraoka, Y. Imamura, M. Nakamura, N. Watanabe, N. Date, T. Aizaki, H. Iwamura, T. Narumi, H. Chayama, K. Wakita, T.
PLoS One. 2022 Sep 22;17(9):e0274283. doi: 10.1371/journal.pone.0274283. eCollection 2022.

READ MORE(PUB MED)

Prediction of the human pharmacokinetics of epyrifenacil and its major metabolite, S-3100-CA, by a physiologically based pharmacokinetic modeling using chimeric mice with humanized liver

Hirasawa, K. Abe, J. Nagahori, H. Kitamoto, S.
Toxicol Appl Pharmacol. 2022 Mar 15;439:115912. doi: 10.1016/j.taap.2022.115912.

READ MORE(PUB MED)

Discovery of a first-in-class orally available HBV cccDNA inhibitor

Wang, L. Zhu, Q. Zhang, J. D. Zhang, Y. Ni, X. Xiang, K. Jiang, J. Li, B. Yu, Y. Hu, H. Zhang, M. Wu, W. Zeng, J. Yan, Z. Dai, J. Sun, K. Zhang, X. Chen, D. Feng, S. Sach Peltason, L. Young, J. A. T. Gao, L.
J Hepatol. 2022 Dec 29:S0168-8278(22)03466-3. doi: 10.1016/j.jhep.2022.12.014.

READ MORE(PUB MED)

Characterization and Prevention of Hypovitaminosis C in Chimeric Mice with Humanized Livers

Touchette, Erin K. Bates, Maria C. Johnson, Mitch C. O’Brien, Tracy C. Melton, Roger J. Long, Kelly R. Kakuni, Masakazu, Baginski, Matthew, Radiloff, Daniel R. Sagartz, John E.
Comparative Medicine 2022, 72(6): 355-363.

READ MORE(PUB MED)

Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus

Gilmore, S. A. Tam, D. Cheung, T. L. Snyder, C. Farand, J. Dick, R.Matles, M. Feng, J. Y.Ramirez, R.Li, L. Yu, H. Xu, Y.Barnes, D. Czerwieniec, G. Brendza, K. M. Appleby, T. C. Birkus, G. Willkom, M. Kobayashi, T. Paoli, E. Labelle, M. Boesen, T.Tay, C. H. Delaney, W. E. thNotte, G. T. Schmitz, U. Feierbach, B.
PLoS One. 2022 Dec 7;17(12):e0271145. doi: 10.1371/journal.pone.0271145. eCollection 2022.

READ MORE(PUB MED)

Physiologically based pharmacokinetic modeling for quantitative prediction of exposure to a human disproportionate metabolite of the selective Na(v)1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase, using chimeric mice with humanized liver

Asano, D. Nakamura, K. Nishiya, Y. Shiozawa, H. Takakusa, H. Shibayama, T. Inoue, S. I. Shinozuka, T. Hamada, T. Yahara, C. Watanabe, N. Yoshinari, K.
Drug Metab Dispos. 2023 Jan;51(1):67-80. doi: 10.1124/dmd.122.001000. Epub 2022 Oct 23.

READ MORE(PUB MED)

Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions

Sakai, K. Sugano-Nakamura, N. Mihara, E. Rojas-Chaverra, N. M. Watanabe, S. Sato, H. Imamura, R. Voon, D. C. Sakai, I. Yamasaki, C. Tateno, C. Shibata, M. Suga, H. Takagi, J. Matsumoto, K.
Nat Biomed Eng. 2022 Nov 7. doi: 10.1038/s41551-022-00955-6.

READ MORE(PUB MED)

Evaluation of the mode of action and human relevance of liver tumors in male mice treated with epyrifenacil

Fukunaga, S. Ogata, K. Eguchi, A. Matsunaga, K. Sakurai, K. Abe, J. Cohen, S. M. Asano, H.
Regul Toxicol Pharmacol. 2022 Oct 6;136:105268. doi: 10.1016/j.yrtph.2022.105268.

READ MORE(PUB MED)

Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression

Sakai, N. Kamimura, K. Miyamoto, H. Ko, M. Nagoya, T. Setsu, T. Sakamaki, A. Yokoo, T. Kamimura, H. Soki, H. Tokunaga, A. Inamine, T. Nakashima, M. Enomoto, H. Kousaka, K. Tachiki, H.
J Gastroenterol. 2022 Oct 27. doi: 10.1007/s00535-022-01929-w.

READ MORE(PUB MED)

Targeting lipid biosynthesis pathways for hepatitis B virus cure

Hyrina, A. Burdette, D. Song, Z. Ramirez, R. Okesli-Armlovich, A. Vijayakumar, A. Bates, J. Trevaskis, J. L. Fletcher, S. P. Lee, W. A. Holdorf, M. M.
PLoS One. 2022 Aug 4;17(8):e0270273. doi: 10.1371/journal.pone.0270273. eCollection 2022.

READ MORE(PUB MED)

Downregulation of CYP17A1 by 20-hydroxyecdysone: plasma progesterone and its vasodilatory properties

Aljaber, M. Y. Orie, N. N. Raees, A. Kraiem, S. Al-Jaber, M. Samsam, W. Hamza, M. M. Abraham, D. Kneteman, N. M. Beotra, A. Mohamed-Ali, V. Almaadheed, M.
Future Sci OA. 2022 Jul 7;8(6):FSO805. doi: 10.2144/fsoa-2022-0006. eCollection 2022 Jul.

READ MORE(PUB MED)

Signature of chronic hepatitis B virus infection in nails and hair

Komatsu, H. Inui, A. Odmaa, E. Ito, Y. Hoshino, H. Umetsu, S. Tsunoda, T. Fujisawa, T.
BMC Infect Dis. 2022 May 4;22(1):431. doi: 10.1186/s12879-022-07400-8.

READ MORE(PUB MED)

Assessment of metabolic activation of felbamate in chimeric mice with humanized liver in combination with in vitro metabolic assays

Sato, K. Sanoh, S. Ishida, Y. Tateno, C. Ohta, S. Kotake, Y.
J Toxicol Sci. 2022;47(7):277-288. doi: 10.2131/jts.47.277.

READ MORE(PUB MED)

IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH

Xu, J. Wang, Y. Khoshdeli, M. Peach, M. Chuang, J. C. Lin, J. Tsai, W. W. Mahadevan, S. Minto, W. Diehl, L. Gupta, R. Trauner, M. Patel, K. Noureddin, M. Kowdley, K. V. Gulamhusein, A. Bowlus, C. L. Huss, R. S. Myers, R. P. Chung, C. Billin, A. N.
Hepatology. 2022 Jun 10. doi: 10.1002/hep.32599.

READ MORE(PUB MED)